TEM | NASDAQ
Next Earnings: Jun 17, 2026
Company Overview:
2 Year TEM Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
Get 3 months FREE!
TEM Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for TEM
Based on past 2-year performance, here are TEM growth metrics:
Share price CAGR of +10.12%
Dividend CAGR of +0%
Using TEM CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| TEM (DRIP) | TEM - No DRIP | |
|---|---|---|
| Current Price | $48.81 | $48.81 |
| Start Shares | 204.88 | 204.88 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 204.88 | 204.88 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $116.24 | $48.81 |
| Total Dividends | $0 | $0 |
| Final Value | $23,815 | $10,000 |
NOTE: Above numbers are our estimate based on TEM's Dividend and Price CAGR over past 2 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Get 3 months FREE!
Company Info
Tempus AI, Inc. (TEM) had its IPO on 2012-03-28, and is trader on NASDAQ stock exchange.
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc in January 2023. Tempus AI, Inc was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM website: https://www.tempus.com
Get Full Access to All Reports with DRIPCalc PRO
Get 3 months FREE!
